You just read:

Imago BioSciences Doses First Patients in the Phase 2a Portion of the Study of IMG-7289 in Acute Myeloid Leukemia and Myelodysplastic Syndrome

News provided by

Imago BioSciences

Jul 19, 2017, 09:00 ET